deltatrials
Unknown PHASE1 NCT00986661

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant

Sponsor: Provectus Biopharmaceuticals, Inc.

Conditions Cancer Metastatic to the Liver Hepatocellular Carcinoma Metastatic Breast Cancer Metastatic Colon Cancer Metastatic Colorectal Cancer Metastatic Lung Cancer Metastatic Melanoma Metastatic Ocular Melanoma Metastatic Pancreatic Cancer Metastatic Uveal Melanoma
Interventions PV-10 (10% rose bengal disodium)
Updated 22 times since 2017 Last updated: Oct 31, 2022 Started: Oct 31, 2009 Primary completion: Dec 31, 2022 Completion: Feb 28, 2023

This PHASE1 trial investigates Cancer Metastatic to the Liver and Hepatocellular Carcinoma and is currently ongoing. Provectus Biopharmaceuticals, Inc. leads this study, which shows 22 recorded versions since 2009 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

22 versions recorded

  1. Nov 2024 — Present [monthly]

    Unknown PHASE1

    Status: Active Not Recruiting → Unknown

  2. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Dec 2022 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Apr 2022 — Dec 2022 [monthly]

    Recruiting PHASE1

▶ Show 17 earlier versions

  1. Sep 2021 — Apr 2022 [monthly]

    Recruiting PHASE1

  2. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  3. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE1

  4. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE1

  5. Apr 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  6. Feb 2020 — Apr 2020 [monthly]

    Recruiting PHASE1

  7. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE1

  8. Sep 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

  9. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE1

  10. May 2019 — Aug 2019 [monthly]

    Recruiting PHASE1

  11. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE1

  12. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE1

  13. Jun 2018 — Mar 2019 [monthly]

    Recruiting PHASE1

  14. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  15. Feb 2018 — May 2018 [monthly]

    Recruiting PHASE1

  16. Feb 2017 — Feb 2018 [monthly]

    Recruiting PHASE1

  17. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Oct 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Provectus Biopharmaceuticals, Inc.
Data source: Provectus Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethlehem, United States
  • • Houston, United States
  • • Nashville, United States
  • • San Diego, United States
  • • Tampa, United States